KR102128810B1 - 요산 또는 통풍 질환의 예방 또는 치료 - Google Patents

요산 또는 통풍 질환의 예방 또는 치료 Download PDF

Info

Publication number
KR102128810B1
KR102128810B1 KR1020177024392A KR20177024392A KR102128810B1 KR 102128810 B1 KR102128810 B1 KR 102128810B1 KR 1020177024392 A KR1020177024392 A KR 1020177024392A KR 20177024392 A KR20177024392 A KR 20177024392A KR 102128810 B1 KR102128810 B1 KR 102128810B1
Authority
KR
South Korea
Prior art keywords
uric acid
purine
dione
chloro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177024392A
Other languages
English (en)
Korean (ko)
Other versions
KR20170106485A (ko
Inventor
치안 장
전화 황
진롱 리우
셩셩 치
Original Assignee
샨톤 파르마 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샨톤 파르마 씨오., 엘티디. filed Critical 샨톤 파르마 씨오., 엘티디.
Publication of KR20170106485A publication Critical patent/KR20170106485A/ko
Application granted granted Critical
Publication of KR102128810B1 publication Critical patent/KR102128810B1/ko
Assigned to 샨톤 파르마 피티이. 엘티디. reassignment 샨톤 파르마 피티이. 엘티디. 권리의 전부이전등록 Assignors: 샨톤 파르마 씨오., 엘티디.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177024392A 2015-01-30 2016-01-28 요산 또는 통풍 질환의 예방 또는 치료 Active KR102128810B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201510048096 2015-01-30
CN201510048096.3 2015-01-30
CN201510080714.2 2015-02-13
CN201510079809 2015-02-13
CN201510079809.2 2015-02-13
CN201510080714 2015-02-13
CN201510216089.X 2015-04-30
CN201510216089 2015-04-30
PCT/CN2016/000061 WO2016119570A1 (zh) 2015-01-30 2016-01-28 尿酸性或痛风性疾病的预防或治疗

Publications (2)

Publication Number Publication Date
KR20170106485A KR20170106485A (ko) 2017-09-20
KR102128810B1 true KR102128810B1 (ko) 2020-07-02

Family

ID=56542370

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024392A Active KR102128810B1 (ko) 2015-01-30 2016-01-28 요산 또는 통풍 질환의 예방 또는 치료

Country Status (26)

Country Link
US (1) US10322132B2 (https=)
EP (1) EP3251675B1 (https=)
JP (1) JP6678685B2 (https=)
KR (1) KR102128810B1 (https=)
CN (1) CN107206002B (https=)
AU (1) AU2016212625B2 (https=)
BR (1) BR112017016065A2 (https=)
CA (1) CA2973746C (https=)
CY (1) CY1124383T1 (https=)
DK (1) DK3251675T3 (https=)
EA (1) EA034139B1 (https=)
ES (1) ES2881872T3 (https=)
HR (1) HRP20211007T1 (https=)
HU (1) HUE054741T2 (https=)
IL (1) IL253726B2 (https=)
LT (1) LT3251675T (https=)
MA (1) MA41431B1 (https=)
MX (1) MX380301B (https=)
PL (1) PL3251675T3 (https=)
PT (1) PT3251675T (https=)
SG (2) SG11201705889VA (https=)
SI (1) SI3251675T1 (https=)
SM (1) SMT202100359T1 (https=)
TW (1) TWI680761B (https=)
WO (1) WO2016119570A1 (https=)
ZA (1) ZA201704600B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
US20260035370A1 (en) 2023-02-27 2026-02-05 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor
CN116650490B (zh) * 2023-06-07 2025-05-20 中国人民解放军海军军医大学 化合物mt-1207在降低尿酸方面的应用
EP4497439A1 (en) * 2023-07-28 2025-01-29 Universitat de les Illes Balears Compounds for the treatment or prevention of gout
TWI902254B (zh) * 2024-05-16 2025-10-21 新加坡商珊頓醫藥科技新加坡公司 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016699A1 (en) 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
US20110136835A1 (en) 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CN101479273B (zh) * 2006-06-23 2011-11-30 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
KR20090025262A (ko) * 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016699A1 (en) 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
US20110136835A1 (en) 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Also Published As

Publication number Publication date
JP6678685B2 (ja) 2020-04-08
ZA201704600B (en) 2020-07-29
SG11201705889VA (en) 2017-08-30
ES2881872T3 (es) 2021-11-30
LT3251675T (lt) 2021-07-12
PT3251675T (pt) 2021-05-25
CN107206002B (zh) 2019-07-16
WO2016119570A1 (zh) 2016-08-04
MA41431A (fr) 2017-12-06
CN107206002A (zh) 2017-09-26
AU2016212625A1 (en) 2017-07-27
EA201791714A1 (ru) 2017-11-30
BR112017016065A2 (pt) 2018-04-03
SI3251675T1 (sl) 2021-08-31
HK1244434A1 (zh) 2018-08-10
TW201628623A (zh) 2016-08-16
IL253726A0 (en) 2017-09-28
JP2018503691A (ja) 2018-02-08
DK3251675T3 (da) 2021-06-28
CA2973746C (en) 2020-03-24
HK1245146A1 (en) 2018-08-24
HRP20211007T1 (hr) 2021-09-17
EP3251675B1 (en) 2021-04-21
MX2017009853A (es) 2017-11-01
EP3251675A1 (en) 2017-12-06
MX380301B (es) 2025-03-12
US10322132B2 (en) 2019-06-18
SMT202100359T1 (it) 2021-07-12
HUE054741T2 (hu) 2021-09-28
US20170326148A1 (en) 2017-11-16
MA41431B1 (fr) 2021-05-31
TWI680761B (zh) 2020-01-01
AU2016212625B2 (en) 2020-03-26
EA034139B1 (ru) 2020-01-09
SG10201907026RA (en) 2019-09-27
IL253726B1 (en) 2023-03-01
IL253726B2 (en) 2023-07-01
CY1124383T1 (el) 2022-07-22
CA2973746A1 (en) 2016-08-04
PL3251675T3 (pl) 2021-11-02
KR20170106485A (ko) 2017-09-20
EP3251675A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
KR20230145439A (ko) Irak4 분해제 및 이의 용도
KR102128810B1 (ko) 요산 또는 통풍 질환의 예방 또는 치료
WO2021135654A1 (zh) 双硫仑在制备防治nlrp3炎症小体相关疾病的药物中的应用
EP3536320A1 (en) Application of hedgehog pathway inhibitor for treatment of fibrotic diseases
KR101390144B1 (ko) 염증성 장질환 치료제
WO2020177744A1 (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
CN111093661B (zh) 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途
JP6860677B2 (ja) グローコカリキシンａ誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用
CN105272984B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
HK1245146B (en) Prevention or treatment of uric acid or gout disease
HK1244434B (zh) 尿酸性或痛风性疾病的预防或治疗
JP3834089B2 (ja) ベンズイミダゾール誘導体を含有するぜん息治療剤
CN114828856B (zh) 以稠合嘧啶化合物为有效成分的治疗剂
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
JPH08239322A (ja) ピロリジノン誘導体を含有する医薬組成物
CN106459053B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
HK40073574A (en) Therapeutic agent containing fused pyrimidine compound as active ingredient
CN113234013A (zh) 一种抑制胶原合成和沉积的化合物及其应用
HK40028225A (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
JP2001523242A (ja) 炎症治療薬の調製のためのミゾラスチンの使用
HK1127964B (en) Therapeutic agent for inflammatory bowel disease
JPWO2001021177A1 (ja) ケモカイン・サイトカイン発現抑制剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000